A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.
Also called NCT06202079
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 179 participants
- Registry
-
NCT06202079
-
- Other papers using this trial's data
- Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06202079. Randomized; no masking; primary purpose treatment. Start 2023-08-11 (actual); primary completion 2024-07-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- GZR4 Injection
- Intervention (Drug)
- Insulin Degludec
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
Record details
- Record id
cardio:ct-nct06202079- Content hash
6e7d26c5bcea0ec7fc8ac985aebf1db8c3002b4350f90f9b968c8c1041070df1